Roche RHHBY announced positive top-line results from an early-stage study on its experimental obesity candidate CT-996. The study is a multi-part, multi-cohort phase I randomized, double-blind, placebo-controlled, single and multiple-ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-996 in otherwise-healthy adults who are overweight or obese, with and without type 2 diabetes. CT-996 is an investigational, once-daily, oral small-molecule GLP-1 receptor agonist, being developed for the treatment of both type 2 diabetes and obesity. Part 1 was a single ascending dose in 40 overweight participants (completed), while part 2 was a multiple ascending dose in three sequential cohorts of a total of 25 participants with obesity without type 2 diabetes (completed). Part 3 is a multiple ascending dose study in two sequential cohorts of 30 participants with obesity and type 2 diabetes (planned to be initiated in the fourth quarter). Data from two arms of the ongoing phase I study showed that treatment with CT-996 in participants with obesity and without type 2 diabetes resulted in a clinically meaningful placebo-adjusted mean weight loss of 6.1% within four weeks. The candidate was well tolerated, with mostly mild or moderate gastrointestinal-related adverse events, consistent with the safety profile of the incretin drug class. No unexpected safety signal was observed and there wasn’t any treatment discontinuation related to the drug under study. The pharmacokinetic data supports a once-daily oral dosing regimen for CT-996. Year to date, Roche’s shares gained 0.1% compared to the industry’s 23.4% growth. Zacks Investment Research Image Source: Zacks Investment Research Roche forayed into the obesity market when it acquired privately owned Carmot Therapeutics for $2.7 billion. The acquisition added a differentiated incretin portfolio with three candidates — CT-388, CT-996 and CT-868 — to its pipeline. CT-388 is an investigational dual GLP-1/GIP receptor agonist for the treatment of obesity in patients with and without type 2 diabetes. The candidate is currently in phase II. CT-868 is an investigational, once-daily, subcutaneously injected dual GLP-1/GIP receptor agonist, currently in phase II, with the potential to be a first-in-class treatment for glycaemic control as an adjunct to insulin in patients living with type 1 diabetes. In May 2024, Roche announced positive results from an early-stage study evaluating CT-388. Over 24 weeks, patients who received this once-weekly, subcutaneously-injected drug achieved a mean placebo-adjusted weight loss of 18.8%. Per Roche, this recently acquired incretin-based portfolio could also be expanded to other indications where incretins play a role, including cardiovascular and kidney diseases. The obesity market is currently one of the most lucrative spaces in the healthcare sector, dominated by bigwigs like Novo Nordisk NVO and Eli Lilly LLY. The stupendous success of Novo Nordisk’s obesity drug Wegovy put the spotlight on the obesity space. The FDA approved Weogovy in 2021 for chronic weight management in obese or overweight adults. Since the approval, sales of the drug have been rising consistently, driven by increased demand. Eli Lilly’s Zepbound also witnessed a strong uptake, owing to solid demand. Given the significant market potential of obesity, other players are striving to grab a share of this pie as well. Zacks Rank Roche currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY):Free Stock Analysis Report Novo Nordisk A/S (NVO):Free Stock Analysis Report Eli Lilly and Company (LLY):Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research
Roche (RHHBY) Reports Positive Phase I Data on Obesity Drug
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...